Puretech Health confirms possible tie-up with Nektar Therapeutics
PureTech Health
208.00p
11:14 23/04/24
1.22%
2.50p
PureTech Health said on Friday that it has exchanged indicative, non-binding proposals with US biopharmaceutical company Nektar Therapeutics regarding a possible combination.
FTSE 250
19,708.75
11:15 23/04/24
n/a
n/a
FTSE 350
4,426.57
11:15 23/04/24
n/a
n/a
FTSE All-Share
4,380.74
11:15 23/04/24
n/a
n/a
Nektar Therapeutics
$1.36
12:39 22/04/24
9.68%
$0.12
Pharmaceuticals & Biotechnology
21,855.95
11:15 23/04/24
0.30%
65.75
Responding to press speculation a day earlier, PureTech said that it remains in discussions with Nektar about the proposal.
There can be no certainty that any firm offer will be made, nor as to the terms of any such offer, it said, adding that a further announcement will be made as and when appropriate.
Under UK takeover rules, Nektar has until 1700 BST on 3 November to either announce a firm intention to make an offer for the company or walk away.